GS US 454 4378: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IP in Subjects with Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)

March 09, 2018
Gastroenterology Hepatology
Principal Investigator: Kimberly A Brown, MD
liver, fatty, NASH, nonalcoholic, steatohepatitis, hepatology, gastroenterology
Accepting Participants